Features of the in vitro established rat large granular lymphocyte leukaemia RNK-16. 1988

I Axberg, and M Nose, and C W Reynolds, and H Wigzell
Department of Immunology, Karolinska Institute, Stockholm, Sweden.

A large granular lymphocyte (LGL) leukaemia cell line from the Fisher/F344 rat strain called RNK-16 has been established in vitro, maintaining the same surface markers as tumour cell growing in vivo. The tumour has also maintained its specificity pattern and cytotoxic reactivity and serves as a suitable source of natural killer (NK)-like effector cells in vitro. The cells show no evidence of dependency on, or production of, interleukin 2 or interferons, nor is the cytotoxic capacity influenced by treatment with mitogens. The in vitro line does not produce natural killer cytotoxic factor (NKCF) in a constitutive manner, but can be induced to do so via coculture with tumour target cells. When the fine specificity patterns were analysed, the RNK-16 cells express species-preferential lysis of susceptible target cells and a highly discriminatory power to kill only 1 out of 5 rat erythroleukaemia cell lines. When testing normal target susceptibility patterns, RNK-16 kills lymphoblasts of B type better than T blasts, which is well in line with previous findings on normal NK cell specificity patterns.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D007942 Leukemia, Experimental Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues. Experimental Leukemia,Experimental Leukemias,Leukemia Model, Animal,Leukemias, Experimental,Animal Leukemia Model,Animal Leukemia Models,Leukemia Models, Animal
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008808 Mice, Inbred CBA An inbred strain of mouse that is widely used in BIOMEDICAL RESEARCH. Mice, CBA,Mouse, CBA,Mouse, Inbred CBA,CBA Mice,CBA Mice, Inbred,CBA Mouse,CBA Mouse, Inbred,Inbred CBA Mice,Inbred CBA Mouse
D008811 Mice, Inbred DBA An inbred strain of mouse. Specific substrains are used in a variety of areas of BIOMEDICAL RESEARCH such as DBA/1J, which is used as a model for RHEUMATOID ARTHRITIS. Mice, DBA,Mouse, DBA,Mouse, Inbred DBA,DBA Mice,DBA Mice, Inbred,DBA Mouse,DBA Mouse, Inbred,Inbred DBA Mice,Inbred DBA Mouse
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D011916 Rats, Inbred F344 An inbred strain of rat that is used for general BIOMEDICAL RESEARCH purposes. Fischer Rats,Rats, Inbred CDF,Rats, Inbred Fischer 344,Rats, F344,Rats, Inbred Fisher 344,CDF Rat, Inbred,CDF Rats, Inbred,F344 Rat,F344 Rat, Inbred,F344 Rats,F344 Rats, Inbred,Inbred CDF Rat,Inbred CDF Rats,Inbred F344 Rat,Inbred F344 Rats,Rat, F344,Rat, Inbred CDF,Rat, Inbred F344,Rats, Fischer
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D005260 Female Females

Related Publications

I Axberg, and M Nose, and C W Reynolds, and H Wigzell
November 2022, Australian veterinary journal,
I Axberg, and M Nose, and C W Reynolds, and H Wigzell
January 1989, Journal of immunology (Baltimore, Md. : 1950),
I Axberg, and M Nose, and C W Reynolds, and H Wigzell
October 1987, British journal of haematology,
I Axberg, and M Nose, and C W Reynolds, and H Wigzell
August 1989, Journal of clinical pathology,
I Axberg, and M Nose, and C W Reynolds, and H Wigzell
June 2014, Journal of neurology,
I Axberg, and M Nose, and C W Reynolds, and H Wigzell
March 2000, British journal of haematology,
I Axberg, and M Nose, and C W Reynolds, and H Wigzell
January 2016, The Lancet. Haematology,
I Axberg, and M Nose, and C W Reynolds, and H Wigzell
August 1988, British journal of haematology,
I Axberg, and M Nose, and C W Reynolds, and H Wigzell
June 1998, British journal of haematology,
I Axberg, and M Nose, and C W Reynolds, and H Wigzell
September 2004, Rheumatology (Oxford, England),
Copied contents to your clipboard!